Physician profile

Johan E Samanta

Neurology (Psychiatry & Neurology) · Phoenix, AZ

NPI 1487653739

$146,043.11

in general payments reported to CMS, 2019-2025

49 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Consulting Fee$13,647.50
Food and Beverage$3,873.85
Travel and Lodging$1,909.92
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program$1,855.00
Education$6.32

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Neurocrine Biosciences, INC. $74,289.71 2019-2023 Ingrezza, Ongentys
Acorda Therapeutics, INC $45,232.67 2019-2023 Inbrija
Teva Pharmaceuticals USA, INC. $4,413.16 2019-2023 Austedo Xr, Austedo
Sunovion Pharmaceuticals INC. $3,796.07 2020-2022
Abbvie INC. $3,521.06 2019-2023 Botox, Duopa, Qulipta
Acadia Pharmaceuticals INC $1,811.73 2019-2023 Nuplazid
Jazz Pharmaceuticals INC. $1,653.19 2022
Medtronic, INC. $1,540.78 2021-2022
Mdd US Operations, LLC $1,200.75 2020-2023 Apokyn, Xadago
Amneal Pharmaceuticals LLC $1,135.25 2019-2023 Rytary
Medtronic USA, INC. $1,082.57 2019-2020
Allergan, INC. $780.14 2019-2022
Abbott Laboratories $698.34 2019-2023 Infinity
Ucb, INC. $631.71 2019-2021
Boston Scientific Corporation $563.80 2019-2023
Show all 47 companies
CompanyGeneral paymentsYearsTop products
Lundbeck LLC $368.72 2019-2023 Vyepti
Avion Pharmaceuticals $265.71 2022-2023 Dhivy
Emd Serono, INC. $265.56 2020-2023 Mavenclad
Kyowa Kirin, INC. $257.84 2019-2023 Nourianz
Ipsen Biopharmaceuticals, INC $212.33 2019-2023 Dysport
Merz Pharmaceuticals, LLC $192.77 2021-2023 Xeomin
Adamas Pharmaceuticals, INC. $191.05 2019-2021
Avanir Pharmaceuticals, INC. $150.17 2019
Lilly USA, LLC $145.70 2019-2023 Amyvid
Idorsia Pharmaceuticals US INC $123.48 2023
Amgen INC. $115.54 2019-2021
Vertical Pharmaceuticals, LLC $103.59 2019-2020
Novartis Pharmaceuticals Corporation $100.45 2019-2021
Alexion Pharmaceuticals, INC. $88.65 2019-2020
Upsher-Smith Laboratories LLC $78.53 2019-2020
Biohaven Pharmaceutical Holding Company Ltd. $78.44 2022
Merz North America, INC. $66.40 2019-2020
Insightec,INC $57.19 2023 Exablate
Biohaven Pharmaceuticals, INC. $52.33 2021
Otsuka America Pharmaceutical, INC. $48.89 2023 Nuedexta
Biogen, INC. $45.34 2020-2021
Sk Life Science, INC. $39.83 2020
Zyla Life Sciences, INC. $38.90 2019
Travere Therapeutics, INC. $25.22 2022
Greenwich Biosciences, INC. $24.54 2020
Mallinckrodt Enterprises LLC $22.60 2019
Horizon Therapeutics Plc $19.00 2022
Grifols USA, LLC $17.91 2020
Promius Pharma LLC $15.95 2019
Alfasigma USA, INC. $15.65 2020
Ge Healthcare $15.52 2019
Arbor Pharmaceuticals, INC. $12.63 2022

2 companies reported research payments only; those appear in the research section below.

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Johan E Samanta

$146,043.11

in general payments reported 2019-2025

Years
2019-2023
Top company
Neurocrine Biosciences, INC.

https://glasscript.com/doctor/249270/johan-e-samanta

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.